or Try an Advanced Search...

    Technical Analysis for ERNA - Eterna Therapeutics Inc.

    Grade Last Price % Change Price Change
    F 1.04 -4.59% -0.05
    ERNA closed down 4.59 percent on Friday, November 1, 2024, on 11 percent of normal volume.
    Earnings due: Nov 11
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Up
    Historical ERNA trend table...
    Date Alert Name Type % Chg
    20 DMA Support Bullish 0.00%
    Inside Day Range Contraction 0.00%
    20 DMA Support Bullish -4.59%
    Shooting Star Candlestick Bearish -5.45%
    Volume Surge Other -5.45%
    Doji - Bearish? Reversal -5.45%
    Upper Bollinger Band Touch Strength -5.45%
    20 DMA Support Bullish -5.45%
    Outside Day Range Expansion -5.45%
    Up 3 Days in a Row Strength -5.45%
    Older End-of-Day Signals for ERNA ...

       Recent Intraday Alerts

    Alert Time
    Possible Inside Day about 22 hours ago
    20 DMA Support about 22 hours ago
    60 Minute Opening Range Breakdown about 22 hours ago
    Down 5% about 22 hours ago
    Down 3% about 22 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    ERNA Chart by TradingView
    Basic chart:

    Profile

    Eterna is focused on developing advanced therapies using state-of-the-art mRNA cell engineering technology. Its mission is to realize the potential of cell engineering to provide patients with transformational new medicines. The Company has in-licensed a portfolio of over 100 patents covering key cell engineering technologies, including what it believes are the most widely used methods for therapeutic gene editing currently in clinical development. Eterna has multiple next-generation cell and gene-editing therapies in preclinical development for various indications.
    Classification
    Sector: Consumer Cyclical
    Industry: Broadcasting - TV
    Keywords: Cancer Clinical Medicine Immunology Immune System Immunotherapy Natural Killer Cell T Cell Dendritic Cell

    Is ERNA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 30 Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success
    Oct 18 Eterna, Factor announce license, collaboration agreement
    Oct 17 Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases
    May 8 Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board
    May 7 Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M Locus
    May 7 Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MS...
    See more ERNA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.625
    52 Week Low 0.8349
    Average Volume 38,409
    200-Day Moving Average 1.74
    50-Day Moving Average 1.27
    20-Day Moving Average 1.03
    10-Day Moving Average 1.01
    Average True Range 0.12
    RSI (14) 44.75
    ADX 19.64
    +DI 21.65
    -DI 19.11
    Chandelier Exit (Long, 3 ATRs) 0.88
    Chandelier Exit (Short, 3 ATRs) 1.20
    Upper Bollinger Bands 1.15
    Lower Bollinger Band 0.91
    Percent B (%b) 0.52
    BandWidth 23.32
    MACD Line -0.05
    MACD Signal Line -0.08
    MACD Histogram 0.0275
    Fundamentals Value
    Market Cap 5.63 Million
    Num Shares 5.41 Million
    EPS -3.96
    Price-to-Earnings (P/E) Ratio -0.26
    Price-to-Sales 175.64
    Price-to-Book 2.43
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.14
    Resistance 3 (R3) 1.15 1.13 1.13
    Resistance 2 (R2) 1.13 1.10 1.12 1.12
    Resistance 1 (R1) 1.08 1.08 1.07 1.07 1.11
    Pivot Point 1.06 1.06 1.05 1.05 1.06
    Support 1 (S1) 1.01 1.03 1.00 1.01 0.97
    Support 2 (S2) 0.99 1.01 0.98 0.96
    Support 3 (S3) 0.95 0.99 0.95
    Support 4 (S4) 0.94